Navigation Links
Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
Date:3/19/2012

Chemists at the University of California, San Diego have produced the first high resolution structure of a molecule that when attached to the genetic material of the hepatitis C virus prevents it from reproducing.

Hepatitis C is a chronic infectious disease that affects some 170 million people worldwide and causes chronic liver disease and liver cancer. According to the Centers for Disease Control and Prevention, hepatitis C now kills more Americans each year than HIV.

The structure of the molecule, which was published in a paper in this week's early online edition of the journal Proceedings of the National Academy of Sciences, provides a detailed blueprint for the design of drugs that can inhibit the replication of the hepatitis C virus, which proliferates by hijacking the cellular machinery in humans to manufacture duplicate viral particles.

Finding a way to stop that process could effectively treat viral infections of hepatitis C, for which no vaccine is currently available. But until now scientists have identified few inhibiting compounds that directly act on the virus's ribonucleic acid (RNA) genomethe organism's full complement of genetic material.

"This lack of detailed information on how inhibitors lock onto the viral genome target has hampered the development of better drugs," said Thomas Hermann, an associate professor of chemistry and biochemistry at UC San Diego who headed the research team, which also included scientists from San Diego State University. The team detailed the structure of a molecule that induces the viral RNA to open up a portion of its hinge-like structure and encapsulate the inhibitor like a perfectly fit glove, blocking the ability of the hepatitis C virus to replicate.

The molecule is from a class of compounds called benzimidazoles, known to stop the production of viral proteins in infected human cells. Its three-dimensional atomic structure was determined by X-ray crystallography, a method of mapping the arrangement of atoms within a crystal, in which a beam of X-rays strikes a crystal and causes the beam of light to spread. The angles and intensities of the light beams allowed the scientists to calculate the structure of the viral RNA-inhibitor complex.

"This structure will guide approaches to rationally design better drug candidates and improve the known benzimidazole inhibitors," said Hermann. "Also, the crystal structure demonstrates that the binding pocket for the inhibitors in the hepatitis C virus RNA resembles drug-binding pockets in proteins. This is important to help overcome the notion that RNA targets are so unlike traditional protein targets that drug discovery approaches with small molecule inhibitors are difficult to achieve for RNA."


'/>"/>

Contact: Kim McDonald
kmcdonald@ucsd.edu
858-534-7572
University of California - San Diego
Source:Eurekalert

Related biology news :

1. Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012
2. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
3. A*STAR scientists make groundbreaking discovery on stem cell regulation
4. A biodiversity discovery that was waiting in the wings -- wasp wings, that is
5. OHSU discovery may someday lead to prevention and treatment of sudden infant death syndrome
6. Notre Dame researchers report fundamental malaria discovery
7. Discovery of plant nourishing gene brings hope for increased crop seed yield and food security
8. Discovery could help stem smoking-related diseases
9. Georgetown researchers lead discovery expected to significantly change biomedical research
10. New horned dinosaur announced nearly 100 years after discovery
11. Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2020)... ... June 25, 2020 , ... ... solutions for biopharmaceutical R&D, today announced that it has entered into a ... multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy to ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC , ... that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) ... with severe COVID-19. This is the first study of an XPO1 inhibitor in ...
(Date:6/23/2020)... England (PRWEB) , ... June 23, 2020 , ... ... Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of ... project to support testing operations in the fight against the COVID-19 pandemic in ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast ... bioresearch materials, today announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus ... Tennessee, enables studies of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association ... of DRP-104; and, the other profiles the potent, consistent single agent activity in ...
(Date:6/11/2020)... HOUSTON (PRWEB) , ... June 08, 2020 , ... ... first universal vaccine platform delivered through the use of proprietary clean viral vectors, ... vaccine in the United States. Greffex’s platform is the world’s most successful ...
(Date:6/11/2020)... ... 2020 , ... Reducing carbon emissions has been and will continue to be ... market dips, ways to reduce CO2 is something we can’t avoid. , To ... biofuels being produced today are created from recycled cooking oil or crops. Unfortunately, these ...
Breaking Biology Technology: